RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer" Merck’s sac-TMT is an antibody-drug conjugate (ADC) targeting TROP2, a protein that’s overexpressed in many tumors and plays a part in promoting cancer. The first TROP2-directed ADC, Gilead’s Trodelvy, reached the market in 2020. And AstraZeneca and partner Daiichi Sankyo’s datopotamab deruxtecan, or Dato-DXd, looks likely to be the second in the class to enter the ring, with its two applications currently under review at the FDA. More broadly, with altogether 16 drug candidates in clinical development, TROP2 ranks as the second-hottest ADC target following HER2, according to an April study published in Nature Reviews Drug Discovery.
Merck’s TROP2 rivals, AZ/Daiichi and Gilead, each have extensive phase 3 programs in the works for their respective offerings. Together, the three front-runners have disclosed 33 company-sponsored multinational phase 3 trials, including 11 for Trodelvy and 12 for Dato-DXd. The trials may be completed, ongoing or planned."
https://www.fiercepharma.com/pharma/3-big-pharma-companies-33-phase-3-trials-race-supremacy-adc-field